adalimumab (Humira)
adalimumab is an FDA-licensed reference biologic from AbbVie Inc., with 10 approved follow-on biologics.
Reference product
Humira adalimumab
AbbVie Inc.
View full reference-product record- Approved
- Marketing
- Rx
- Center
- CDER
- Patents
- 66 listed
Molecular structure
Experimental 3D structure for adalimumab from the RCSB Protein Data Bank (PDB 4NYL).

Interactive biological assembly from PDB entry 4NYL. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here, with no need to leave the page.
Exclusivity & patent cliffs
Reference approval
Approval date of the reference adalimumab product.
11 yr ago
Patent 8,911,737 expires
Published Purple Book patent expiration.
4 yr 4 mo ago
Patent 8,974,790 expires
Published Purple Book patent expiration.
4 yr 4 mo ago
Patent 8,992,926 expires
Published Purple Book patent expiration.
4 yr 4 mo ago
Patent 9,546,212 expires
Published Purple Book patent expiration.
4 yr 4 mo ago
Patent 6,805,686 expires
Published Purple Book patent expiration.
3 yr 5 mo ago
Patent 8,906,373 expires
Published Purple Book patent expiration.
3 yr 3 mo ago
Patent 9,067,992 expires
Published Purple Book patent expiration.
3 yr 3 mo ago
Patent 9,085,620 expires
Published Purple Book patent expiration.
3 yr 3 mo ago
Patent 9,090,689 expires
Published Purple Book patent expiration.
3 yr 3 mo ago
Patent 8,961,973 expires
Published Purple Book patent expiration.
1 yr 6 mo ago
Patent 8,961,974 expires
Published Purple Book patent expiration.
1 yr 6 mo ago
Patent 8,986,693 expires
Published Purple Book patent expiration.
1 yr 6 mo ago
Patent 9,061,005 expires
Published Purple Book patent expiration.
1 yr 6 mo ago
Patent 9,187,559 expires
Published Purple Book patent expiration.
1 yr 6 mo ago
Patent 9,512,216 expires
Published Purple Book patent expiration.
1 yr 6 mo ago
Patent 8,808,700 expires
Published Purple Book patent expiration.
4 mo ago
Patent 11,083,792 expires
Published Purple Book patent expiration.
in 7 mo
Patent 8,231,876 expires
Published Purple Book patent expiration.
in 7 mo
Patent 8,883,156 expires
Published Purple Book patent expiration.
in 7 mo
Patent 8,895,009 expires
Published Purple Book patent expiration.
in 7 mo
Patent 8,906,372 expires
Published Purple Book patent expiration.
in 7 mo
Patent 8,916,153 expires
Published Purple Book patent expiration.
in 7 mo
Patent 9,096,666 expires
Published Purple Book patent expiration.
in 7 mo
Patent 9,102,723 expires
Published Purple Book patent expiration.
in 7 mo
Patent 9,273,132 expires
Published Purple Book patent expiration.
in 7 mo
Patent 9,328,165 expires
Published Purple Book patent expiration.
in 7 mo
Patent 9,913,902 expires
Published Purple Book patent expiration.
in 7 mo
Patent 8,926,975 expires
Published Purple Book patent expiration.
in 9 mo
Patent 8,715,664 expires
Published Purple Book patent expiration.
in 10 mo
Patent 8,663,945 expires
Published Purple Book patent expiration.
in 1 yr
Patent 8,906,646 expires
Published Purple Book patent expiration.
in 1 yr
Patent 8,911,964 expires
Published Purple Book patent expiration.
in 1 yr
Patent 9,090,867 expires
Published Purple Book patent expiration.
in 1 yr
Patent 9,234,032 expires
Published Purple Book patent expiration.
in 1 yr
Patent 9,284,371 expires
Published Purple Book patent expiration.
in 1 yr
Patent 8,889,136 expires
Published Purple Book patent expiration.
in 1 yr 1 mo
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
in 1 yr 5 mo
Patent 9,284,370 expires
Published Purple Book patent expiration.
in 1 yr 9 mo
Patent 9,669,093 expires
Published Purple Book patent expiration.
in 1 yr 9 mo
Patent 11,167,030 expires
Published Purple Book patent expiration.
in 2 yr 3 mo
Patent 11,191,834 expires
Published Purple Book patent expiration.
in 2 yr 3 mo
Patent 9,085,619 expires
Published Purple Book patent expiration.
in 2 yr 3 mo
Patent 8,420,081 expires
Published Purple Book patent expiration.
in 3 yr 4 mo
Patent 8,999,337 expires
Published Purple Book patent expiration.
in 4 yr 5 mo
Patent 9,624,295 expires
Published Purple Book patent expiration.
in 4 yr 7 mo
Patent 8,708,968 expires
Published Purple Book patent expiration.
in 5 yr 5 mo
Patent 9,339,610 expires
Published Purple Book patent expiration.
in 5 yr 5 mo
Patent 9,062,106 expires
Published Purple Book patent expiration.
in 5 yr 8 mo
Patent 9,090,688 expires
Published Purple Book patent expiration.
in 5 yr 8 mo
Patent 9,505,834 expires
Published Purple Book patent expiration.
in 5 yr 8 mo
Patent 9,522,953 expires
Published Purple Book patent expiration.
in 5 yr 8 mo
Patent 9,683,033 expires
Published Purple Book patent expiration.
in 5 yr 8 mo
Patent 9,957,318 expires
Published Purple Book patent expiration.
in 5 yr 8 mo
Patent 9,085,618 expires
Published Purple Book patent expiration.
in 6 yr 7 mo
Patent 9,181,337 expires
Published Purple Book patent expiration.
in 6 yr 7 mo
Patent 9,181,572 expires
Published Purple Book patent expiration.
in 6 yr 7 mo
Patent 9,290,568 expires
Published Purple Book patent expiration.
in 6 yr 7 mo
Patent 9,334,319 expires
Published Purple Book patent expiration.
in 6 yr 7 mo
Patent 9,346,879 expires
Published Purple Book patent expiration.
in 6 yr 7 mo
Patent 9,359,434 expires
Published Purple Book patent expiration.
in 6 yr 7 mo
Patent 9,499,616 expires
Published Purple Book patent expiration.
in 6 yr 7 mo
Patent 9,708,400 expires
Published Purple Book patent expiration.
in 6 yr 7 mo
Patent 9,315,574 expires
Published Purple Book patent expiration.
in 6 yr 8 mo
Patent 9,150,645 expires
Published Purple Book patent expiration.
in 6 yr 9 mo
Patent 9,266,949 expires
Published Purple Book patent expiration.
in 6 yr 9 mo
Patent 9,499,614 expires
Published Purple Book patent expiration.
in 7 yr 7 mo
Patent 9,550,826 expires
Published Purple Book patent expiration.
in 8 yr 3 mo
Biosimilars & interchangeables for adalimumab
| Product | Proper name | Applicant | Type | BLA | Approved |
|---|---|---|---|---|---|
| Amjevita | adalimumab-atto | Amgen Inc. | Interchangeable | 761024 | |
| Abrilada | adalimumab-afzb | Pfizer Inc. | Interchangeable | 761118 | |
| Hulio | adalimumab-fkjp | Biocon Biologics Inc. | Interchangeable | 761154 | |
| Cyltezo | adalimumab-adbm | Boehringer Ingelheim Pharmaceuticals, Inc. | Interchangeable | 761058 | |
| Hadlima | adalimumab-bwwd | Samsung Bioepis Co., Ltd. | Interchangeable | 761059 | |
| Idacio | adalimumab-aacf | Fresenius Kabi USA, LLC | Biosimilar 351(k) | 761255 | |
| Yusimry | adalimumab-aqvh | Hong Kong King-Friend Industrial Company Limited | Biosimilar 351(k) | 761216 | |
| Hyrimoz | adalimumab-adaz | Sandoz Inc. | Interchangeable | 761071 | |
| Yuflyma | adalimumab-aaty | CELLTRION, Inc. | Interchangeable | 761219 | |
| Simlandi | adalimumab-ryvk | Alvotech USA Inc. | Interchangeable | 761299 |
Published patents
| Patent | Expires | In |
|---|---|---|
| 8,911,737 | 4 yr 4 mo ago | |
| 8,974,790 | 4 yr 4 mo ago | |
| 8,992,926 | 4 yr 4 mo ago | |
| 9,546,212 | 4 yr 4 mo ago | |
| 6,805,686 | 3 yr 5 mo ago | |
| 8,906,373 | 3 yr 3 mo ago | |
| 9,067,992 | 3 yr 3 mo ago | |
| 9,085,620 | 3 yr 3 mo ago | |
| 9,090,689 | 3 yr 3 mo ago | |
| 8,961,973 | 1 yr 6 mo ago | |
| 8,961,974 | 1 yr 6 mo ago | |
| 8,986,693 | 1 yr 6 mo ago | |
| 9,061,005 | 1 yr 6 mo ago | |
| 9,187,559 | 1 yr 6 mo ago | |
| 9,512,216 | 1 yr 6 mo ago | |
| 8,808,700 | 4 mo ago | |
| 11,083,792 | in 7 mo | |
| 8,231,876 | in 7 mo | |
| 8,883,156 | in 7 mo | |
| 8,895,009 | in 7 mo | |
| 8,906,372 | in 7 mo | |
| 8,916,153 | in 7 mo | |
| 9,096,666 | in 7 mo | |
| 9,102,723 | in 7 mo | |
| 9,273,132 | in 7 mo | |
| 9,328,165 | in 7 mo | |
| 9,913,902 | in 7 mo | |
| 8,926,975 | in 9 mo | |
| 8,715,664 | in 10 mo | |
| 8,663,945 | in 1 yr | |
| 8,906,646 | in 1 yr | |
| 8,911,964 | in 1 yr | |
| 9,090,867 | in 1 yr | |
| 9,234,032 | in 1 yr | |
| 9,284,371 | in 1 yr | |
| 8,889,136 | in 1 yr 1 mo | |
| 9,284,370 | in 1 yr 9 mo | |
| 9,669,093 | in 1 yr 9 mo | |
| 11,167,030 | in 2 yr 3 mo | |
| 11,191,834 | in 2 yr 3 mo | |
| 9,085,619 | in 2 yr 3 mo | |
| 8,420,081 | in 3 yr 4 mo | |
| 8,999,337 | in 4 yr 5 mo | |
| 9,624,295 | in 4 yr 7 mo | |
| 8,708,968 | in 5 yr 5 mo | |
| 9,339,610 | in 5 yr 5 mo | |
| 9,062,106 | in 5 yr 8 mo | |
| 9,090,688 | in 5 yr 8 mo | |
| 9,505,834 | in 5 yr 8 mo | |
| 9,522,953 | in 5 yr 8 mo | |
| 9,683,033 | in 5 yr 8 mo | |
| 9,957,318 | in 5 yr 8 mo | |
| 9,085,618 | in 6 yr 7 mo | |
| 9,181,337 | in 6 yr 7 mo | |
| 9,181,572 | in 6 yr 7 mo | |
| 9,290,568 | in 6 yr 7 mo | |
| 9,334,319 | in 6 yr 7 mo | |
| 9,346,879 | in 6 yr 7 mo | |
| 9,359,434 | in 6 yr 7 mo | |
| 9,499,616 | in 6 yr 7 mo | |
| 9,708,400 | in 6 yr 7 mo | |
| 9,315,574 | in 6 yr 8 mo | |
| 9,150,645 | in 6 yr 9 mo | |
| 9,266,949 | in 6 yr 9 mo | |
| 9,499,614 | in 7 yr 7 mo | |
| 9,550,826 | in 8 yr 3 mo |
adalimumab: frequently asked questions
Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.
Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for adalimumab.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.

